1. Report Introduction 2. Rheumatoid Arthritis (RA) Market Overview at a Glance 2.1. Market Share Distribution of Rheumatoid Arthritis (RA) in 2016 2.2. Market Share Distribution of Rheumatoid Arthritis (RA) in 2028 3. Disease Background and Overview: Rheumatoid Arthritis (RA) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Rheumatoid Arthritis (RA) in 7MM 4.3. Total Prevalent Patient Population of Rheumatoid Arthritis (RA) in 7MM – By Countries 5. Epidemiology of Rheumatoid Arthritis (RA) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.1.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.1.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.1.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.1.6. Treatable Cases of the Rheumatoid Arthritis (RA) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.4.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.4.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.4.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.4.6. Treatable Cases of the Rheumatoid Arthritis (RA) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.5.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.5.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.5.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.5.6. Treatable Cases of the Rheumatoid Arthritis (RA) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.6.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.6.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.6.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.6.6. Treatable Cases of the Rheumatoid Arthritis (RA) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.7.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.7.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.7.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.7.6. Treatable Cases of the Rheumatoid Arthritis (RA) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.8.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.8.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.8.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.8.6. Treatable Cases of the Rheumatoid Arthritis (RA) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) 5.9.3. Sub-Type Specific cases of the Rheumatoid Arthritis (RA) * 5.9.4. Sex- Specific Cases of the Rheumatoid Arthritis (RA) * 5.9.5. Diagnosed Cases of the Rheumatoid Arthritis (RA) 5.9.6. Treatable Cases of the Rheumatoid Arthritis (RA) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Rheumatoid Arthritis (RA) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Rheumatoid Arthritis (RA) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Rheumatoid Arthritis (RA) : 7MM Market Analysis 12.1. 7MM Market Size of Rheumatoid Arthritis (RA) 12.2. 7MM Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) 12.3. 7MM Market Sales of Rheumatoid Arthritis (RA) by Products 13. Rheumatoid Arthritis (RA) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Rheumatoid Arthritis (RA) in United States 13.1.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in United States 13.1.3. Market Sales of Rheumatoid Arthritis (RA) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Rheumatoid Arthritis (RA) in Germany 13.2.1.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in Germany 13.2.1.3. Market Sales of Rheumatoid Arthritis (RA) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Rheumatoid Arthritis (RA) in France 13.2.2.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in France 13.2.2.3. Market Sales of Rheumatoid Arthritis (RA) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Rheumatoid Arthritis (RA) in Italy 13.2.3.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in Italy 13.2.3.3. Market Sales of Rheumatoid Arthritis (RA) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Rheumatoid Arthritis (RA) in Spain 13.2.4.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in Spain 13.2.4.3. Market Sales of Rheumatoid Arthritis (RA) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Rheumatoid Arthritis (RA) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in United Kingdom 13.2.5.3. Market Sales of Rheumatoid Arthritis (RA) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Rheumatoid Arthritis (RA) in Japan 13.3.2. Percentage Share of drugs marketed for Rheumatoid Arthritis (RA) in Japan 13.3.3. Market Sales of Rheumatoid Arthritis (RA) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in 7MM Table 2: Total Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Table 5: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Table 6: Diagnosed Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Table 7: Treatable Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Table 11: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Table 12: Treatable Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Table 14: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Table 15: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Table 16: Diagnosed Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Table 17: Treatable Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Table 21: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Table 22: Treatable Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Table 26: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Table 27: Treatable Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Table 30: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Table 31: Diagnosed Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Table 32: Treatable Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Table 36: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Table 37: Treatable Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 42:7MM- Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 45: United States-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 48: Germany-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 51: France-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 54: Italy-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 57: Spain-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 60:UK-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Table 63: Japan-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in 7MM Figure 2: Total Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Figure 6: Diagnosed Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Figure 7: Treatable Cases of the Rheumatoid Arthritis (RA) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Figure 12: Treatable Cases of the Rheumatoid Arthritis (RA) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Figure 15: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Figure 16: Diagnosed Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Figure 17: Treatable Cases of the Rheumatoid Arthritis (RA) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Figure 22: Treatable Cases of the Rheumatoid Arthritis (RA) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Figure 27: Treatable Cases of the Rheumatoid Arthritis (RA) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Figure 31: Diagnosed Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Figure 32: Treatable Cases of the Rheumatoid Arthritis (RA) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Figure 37: Treatable Cases of the Rheumatoid Arthritis (RA) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 42:7MM- Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 45: United States-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 48: Germany-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 51: France-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 54: Italy-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 57: Spain-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 60:UK-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Rheumatoid Arthritis (RA) in USD MM (2016-2028) Figure 63: Japan-Market Share Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Rheumatoid Arthritis (RA) by Therapies in USD MM (2016-2028)